Analysts Note Stronger Outlook as Kimberly-Clark (KMB) Deepens Its Consumer Health Footprint

Argus analyst John Staszak upgraded Kimberly-Clark Corporation (KMB) to a Buy rating with a $120 price target, citing better-than-expected Q3 earnings and plans to acquire Kenvue. The acquisition of Kenvue, which owns major consumer health brands, is expected to strengthen KMB's position in resilient product categories, making it an appealing value pick for long-term investors. Kimberly-Clark generates most of its revenue through direct sales to retailers and has a broad global footprint serving both consumer and professional markets.